ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > NSP8

NSP8

概要

Name:SARS-CoV-2-3C-like-proteinase
Target Synonym:Papain-like proteinase,p65 homolog,MPro,3CL-PRO,GFL,Growth factor-like peptide,Leader protein,Non-structural protein 1,Non-structural protein 10,Non-structural protein 7,Non-structural protein 6,Non-structural protein 4,Non-structural protein 3,Non-structural protein 2,Non-structural protein 11,Non-structural protein 8,Non-structural protein 9,nsp1,nsp10,nsp11,nsp2,nsp3,nsp4,nsp5,nsp6,nsp7,nsp8,nsp9,ORF1a polyprotein,SARS coronavirus main proteinase,Replicase polyprotein 1a,pp1a,PL-PRO,PL2-PRO
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:27
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
NS8-C5149 SARS-CoV-2 SARS-CoV-2 (COVID-19) NSP8 Protein, His Tag
NS8-C5149-structure
NS8-C5149-sds
ACRO Quality

Synonym Name

NSP8,nsp8

Background

NSP8, forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers. To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. By investigating the entire proteome of SARS-CoV-2, six proteins, including the S protein and five non-structural proteins (nsp3, 3CL-pro, and nsp8-10) were predicted to be adhesins, which are crucial to the viral adhering and host invasion. The S, nsp3, and nsp8 proteins were also predicted by Vaxign-ML to induce high protective antigenicity.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Atilotrelvir/Ritonavir Approved Fujian Guangsheng Zhonglin Biotechnology Co Ltd 泰中定 Mainland China Coronavirus Disease 2019 (COVID-19) Fujian Guangsheng Zhonglin Biotechnology Co Ltd 2023-11-23 Coronavirus Disease 2019 (COVID-19) Details
Simnotrelvir SIM-0417; SSD-8432; VV-934 Approved Jiangsu Simcere Pharmaceutical Co Ltd Mainland China Coronavirus Disease 2019 (COVID-19) Jiangsu Simcere Pharmaceutical Co Ltd 2023-01-28 Coronavirus Disease 2019 (COVID-19) Details
Leritrelvir RAY-1216; [14C]RAY1216; [14C]-RAY-1216 Approved Guangdong Raynovent Biotech Co Ltd 乐睿灵 Mainland China Coronavirus Disease 2019 (COVID-19) Guangdong Raynovent Biotech Co Ltd 2023-03-23 Coronavirus Disease 2019 (COVID-19); Acute Kidney Injury; Hepatic Insufficiency Details
Simnotrelvir/Ritonavir SIM-0417/Ritonavir; SSD-8432 / Ritonavir; SIM-0417 / Ritonavir; VV934 / Ritonavir Approved Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Jiangsu Simcere Pharmaceutical Co Ltd, Wuhan Institute Of Virology, Chinese Academy Of Sciences 先诺欣 Mainland China Coronavirus Disease 2019 (COVID-19) Jiangsu Simcere Pharmaceutical Co Ltd 2023-01-28 Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Hepatic Insufficiency Details
Ensitrelvir Fumaric Acid S-217622 Approved Shionogi & Co Ltd, Hokkaido University Xocova Japan Coronavirus Disease 2019 (COVID-19) Shionogi & Co Ltd 2022-11-22 Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Post-Acute COVID-19 Syndrome; Coronaviridae Infections; Hepatic Insufficiency Details
Nirmatrelvir/Ritonavir Approved Pfizer Inc Paxlovid EU Coronavirus Disease 2019 (COVID-19) Pfizer Europe Ma Eeig 2022-01-28 Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome; Coronaviridae Infections Details
Atilotrelvir/Ritonavir Approved Fujian Guangsheng Zhonglin Biotechnology Co Ltd 泰中定 Mainland China Coronavirus Disease 2019 (COVID-19) Fujian Guangsheng Zhonglin Biotechnology Co Ltd 2023-11-23 Coronavirus Disease 2019 (COVID-19) Details
Simnotrelvir SIM-0417; SSD-8432; VV-934 Approved Jiangsu Simcere Pharmaceutical Co Ltd Mainland China Coronavirus Disease 2019 (COVID-19) Jiangsu Simcere Pharmaceutical Co Ltd 2023-01-28 Coronavirus Disease 2019 (COVID-19) Details
Leritrelvir RAY-1216; [14C]RAY1216; [14C]-RAY-1216 Approved Guangdong Raynovent Biotech Co Ltd 乐睿灵 Mainland China Coronavirus Disease 2019 (COVID-19) Guangdong Raynovent Biotech Co Ltd 2023-03-23 Coronavirus Disease 2019 (COVID-19); Acute Kidney Injury; Hepatic Insufficiency Details
Simnotrelvir/Ritonavir SIM-0417/Ritonavir; SSD-8432 / Ritonavir; SIM-0417 / Ritonavir; VV934 / Ritonavir Approved Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Jiangsu Simcere Pharmaceutical Co Ltd, Wuhan Institute Of Virology, Chinese Academy Of Sciences 先诺欣 Mainland China Coronavirus Disease 2019 (COVID-19) Jiangsu Simcere Pharmaceutical Co Ltd 2023-01-28 Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Hepatic Insufficiency Details
Ensitrelvir Fumaric Acid S-217622 Approved Shionogi & Co Ltd, Hokkaido University Xocova Japan Coronavirus Disease 2019 (COVID-19) Shionogi & Co Ltd 2022-11-22 Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Post-Acute COVID-19 Syndrome; Coronaviridae Infections; Hepatic Insufficiency Details
Nirmatrelvir/Ritonavir Approved Pfizer Inc Paxlovid EU Coronavirus Disease 2019 (COVID-19) Pfizer Europe Ma Eeig 2022-01-28 Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome; Coronaviridae Infections Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Ebselen SPI-1005; SPI-3005; PZ-51; DR-3305 Phase 3 Clinical Sound Pharmaceuticals Inc, Daiichi Sankyo Co Ltd Tinnitus; Head and Neck Neoplasms; Diabetes Mellitus, Type 1; Ototoxicity; Diabetes Mellitus, Type 2; Coronavirus Disease 2019 (COVID-19); Small Cell Lung Carcinoma; Bipolar Disorder; Neoplasms; Hearing Loss; Coronavirus Infections; Depressive Disorder, Treatment-Resistant; Lung Neoplasms; Hearing Loss, Noise-Induced; Meniere Disease; Mental Disorders Details
Olgotrelvir STI1558; STI-1558 Phase 3 Clinical Texas A&M University Coronavirus Disease 2019 (COVID-19) Details
S-892216 S-892216 Phase 3 Clinical Shionogi & Co Ltd Coronavirus Disease 2019 (COVID-19) Details
Mprosevir WPV-01 Phase 3 Clinical Westlake University Coronavirus Disease 2019 (COVID-19) Details
QLS-1128 QLS-1128 Phase 3 Clinical Qilu Pharmaceutical Co Ltd Coronavirus Disease 2019 (COVID-19) Details
MIR-19 MIR-19 Phase 3 Clinical St. Petersburg Scientific Research Institute of Vaccines and Sera Coronavirus Disease 2019 (COVID-19) Details
Bofutrelvir FB-2001; DC-402234 Phase 3 Clinical Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Frontier Biotechnologies Inc Coronavirus Disease 2019 (COVID-19) Details
Pomotrelvir PBI-0451 Phase 2 Clinical Pardes Biosciences Inc Coronavirus Disease 2019 (COVID-19) Details
SHEN-211 SHEN-211; SHEN211 Phase 2 Clinical Hubei JKT BioPharma Co Ltd Coronavirus Disease 2019 (COVID-19) Details
HS-10517 HS-10517; HS10517 Phase 2 Clinical Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd Coronavirus Disease 2019 (COVID-19) Details
EDP-235 EDP-235 Phase 2 Clinical Enanta Pharmaceuticals Inc Coronavirus Disease 2019 (COVID-19) Details
Tollovir Phase 2 Clinical Todos Medical Ltd Coronavirus Disease 2019 (COVID-19) Details
Pentarlandir SNB-01; SNB-011 Phase 2 Clinical Syneurx International (Taiwan) Corp Coronavirus Disease 2019 (COVID-19) Details
Nirmatrelvir PF-07321332 Phase 2 Clinical Pfizer As Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome; Hepatic Insufficiency Details
CDI-988 CDI988 Phase 1 Clinical Cocrystal Pharma Inc Coronavirus Disease 2019 (COVID-19) Details
CMX-990 CMX-990; CMX990 Phase 1 Clinical The Scripps Research Institute Inc Coronavirus Disease 2019 (COVID-19) Details
WPV-02 WPV-02; WPV02 Phase 1 Clinical Westlake Pharmaceuticals (Hangzhou) Co Ltd Virus Diseases Details
ISM-3312 ISM-3312 Phase 1 Clinical Insilico Medicine Ltd Coronavirus Disease 2019 (COVID-19) Details
SYH-2055 SYH-2055 Phase 1 Clinical CSPC Pharmaceutical Group Ltd Coronavirus Disease 2019 (COVID-19) Details
Atilotrelvir GST-HG171 Phase 1 Clinical Fujian Guangsheng Zhonglin Biotechnology Co Ltd Coronavirus Disease 2019 (COVID-19) Details
ALG-097558 ALG-097558 Phase 1 Clinical Rega Institute, Ku Leuven, Aligos Therapeutics Inc Coronavirus Disease 2019 (COVID-19) Details
ASC11 ASC-11 Phase 1 Clinical Ascletis Pharma Inc Coronavirus Disease 2019 (COVID-19) Details
Lufotrelvir PF-07304814 Phase 1 Clinical Pfizer Inc Coronavirus Disease 2019 (COVID-19); Virus Diseases Details
Travatrelvir TRX-01 Clinical Traws Pharma Inc Coronavirus Disease 2019 (COVID-19) Details
GS221 GS-221; GS221 Clinical Grand Pharmaceutical （China） Co Ltd Coronavirus Disease 2019 (COVID-19) Details
Ebselen SPI-1005; SPI-3005; PZ-51; DR-3305 Phase 3 Clinical Sound Pharmaceuticals Inc, Daiichi Sankyo Co Ltd Tinnitus; Head and Neck Neoplasms; Diabetes Mellitus, Type 1; Ototoxicity; Diabetes Mellitus, Type 2; Coronavirus Disease 2019 (COVID-19); Small Cell Lung Carcinoma; Bipolar Disorder; Neoplasms; Hearing Loss; Coronavirus Infections; Depressive Disorder, Treatment-Resistant; Lung Neoplasms; Hearing Loss, Noise-Induced; Meniere Disease; Mental Disorders Details
Olgotrelvir STI1558; STI-1558 Phase 3 Clinical Texas A&M University Coronavirus Disease 2019 (COVID-19) Details
S-892216 S-892216 Phase 3 Clinical Shionogi & Co Ltd Coronavirus Disease 2019 (COVID-19) Details
Mprosevir WPV-01 Phase 3 Clinical Westlake University Coronavirus Disease 2019 (COVID-19) Details
QLS-1128 QLS-1128 Phase 3 Clinical Qilu Pharmaceutical Co Ltd Coronavirus Disease 2019 (COVID-19) Details
MIR-19 MIR-19 Phase 3 Clinical St. Petersburg Scientific Research Institute of Vaccines and Sera Coronavirus Disease 2019 (COVID-19) Details
Bofutrelvir FB-2001; DC-402234 Phase 3 Clinical Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Frontier Biotechnologies Inc Coronavirus Disease 2019 (COVID-19) Details
Pomotrelvir PBI-0451 Phase 2 Clinical Pardes Biosciences Inc Coronavirus Disease 2019 (COVID-19) Details
SHEN-211 SHEN-211; SHEN211 Phase 2 Clinical Hubei JKT BioPharma Co Ltd Coronavirus Disease 2019 (COVID-19) Details
HS-10517 HS-10517; HS10517 Phase 2 Clinical Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd Coronavirus Disease 2019 (COVID-19) Details
EDP-235 EDP-235 Phase 2 Clinical Enanta Pharmaceuticals Inc Coronavirus Disease 2019 (COVID-19) Details
Tollovir Phase 2 Clinical Todos Medical Ltd Coronavirus Disease 2019 (COVID-19) Details
Pentarlandir SNB-01; SNB-011 Phase 2 Clinical Syneurx International (Taiwan) Corp Coronavirus Disease 2019 (COVID-19) Details
Nirmatrelvir PF-07321332 Phase 2 Clinical Pfizer As Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome; Hepatic Insufficiency Details
CDI-988 CDI988 Phase 1 Clinical Cocrystal Pharma Inc Coronavirus Disease 2019 (COVID-19) Details
CMX-990 CMX-990; CMX990 Phase 1 Clinical The Scripps Research Institute Inc Coronavirus Disease 2019 (COVID-19) Details
WPV-02 WPV-02; WPV02 Phase 1 Clinical Westlake Pharmaceuticals (Hangzhou) Co Ltd Virus Diseases Details
ISM-3312 ISM-3312 Phase 1 Clinical Insilico Medicine Ltd Coronavirus Disease 2019 (COVID-19) Details
SYH-2055 SYH-2055 Phase 1 Clinical CSPC Pharmaceutical Group Ltd Coronavirus Disease 2019 (COVID-19) Details
Atilotrelvir GST-HG171 Phase 1 Clinical Fujian Guangsheng Zhonglin Biotechnology Co Ltd Coronavirus Disease 2019 (COVID-19) Details
ALG-097558 ALG-097558 Phase 1 Clinical Rega Institute, Ku Leuven, Aligos Therapeutics Inc Coronavirus Disease 2019 (COVID-19) Details
ASC11 ASC-11 Phase 1 Clinical Ascletis Pharma Inc Coronavirus Disease 2019 (COVID-19) Details
Lufotrelvir PF-07304814 Phase 1 Clinical Pfizer Inc Coronavirus Disease 2019 (COVID-19); Virus Diseases Details
Travatrelvir TRX-01 Clinical Traws Pharma Inc Coronavirus Disease 2019 (COVID-19) Details
GS221 GS-221; GS221 Clinical Grand Pharmaceutical （China） Co Ltd Coronavirus Disease 2019 (COVID-19) Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap